Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Collegium Pharmaceutical, a specialty pharmaceutical company, has announced that U.S. Patent No. 8,840,928 has been issued by the U.S. Patent and Trademark Office (USPTO). The issued patent covers the DETERx technology platform.
Subscribe to our email newsletter
As such, the claims provide broad coverage for all opioids and other drugs prone to abuse that could leverage the DETERx technology platform. This is the sixth issued U.S. patent related to the DETERx technology platform and is part of Collegium’s larger portfolio of U.S. and international filings.
Oxycodone DETERx, Collegium’s lead development program, is the first of a number of product candidates utilizing the DETERx technology platform. Collegium recently announced positive Phase 3 study results for Oxycodone DETERx and expects to submit an NDA in the fourth quarter of 2014.
The product has been designated Fast Track Status by the FDA. In addition to the Phase 3 study to establish the safety and efficacy of the product, Collegium has executed a comprehensive development program for evaluation of the product’s abuse-deterrent properties consistent with the FDA’s Draft Guidance, "Abuse-Deterrent Opioids – Evaluation and Labeling."
"These newly allowed claims continue to strengthen and expand our overall patent coverage for the DETERx technology platform. We are continuing to focus on the prosecution of additional patents that support our lead product and the DETERx technology in both the U.S. and internationally," states Michael Heffernan, CEO of Collegium.